ANG Lifesciences India executes Asset purchase deal with Ind-Swift

18 Aug 2021 Evaluate

ANG Lifesciences India has executed an Asset purchase deal with Ind-Swift for acquisition of two formulation manufacturing facilities for Rs 60 crore. payable through internal accrual & bank funding on deferred payment basis up to June 30, 2024, located at Baddi (HP). The plants are now running as Unit 5 & Unit 6 of ANG Lifesciences India respectively. The said acquisition has helped in scaling up ANG’s manufacturing capacity to meet the growing demand from the domestic as well as international markets. 

This acquisition is in line with ANG’s long-term strategic objective to become a complete Healthcare Solution Provider aimed at creating a broad-based basket of Pharmaceutical Formulation Products for a differentiated and comprehensive profile in pharmaceutical markets. 

ANG Lifesciences India, incorporated in the year 2006, started with the business of manufacturing and marketing of finished pharmaceutical formulation in a dosage form of Sterile Dry Powder Injection Vial.

ANG Lifesciences Share Price

53.10 -0.58 (-1.08%)
24-May-2024 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1486.55
Dr. Reddys Lab 5860.25
Cipla 1482.55
Zydus Lifesciences 1072.35
Lupin 1613.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.